Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer.
暂无分享,去创建一个
Stefano Landi | Victor Moreno | Federico Canzian | E. Guinó | V. Moreno | G. Capellá | F. Canzian | S. Landi | J. de Oca | M. Navarro | Gabriel Capella | Lydie Gioia-Patricola | Elisabeth Guino | Matilde Navarro | Javier de Oca | Lydie Gioia-Patricola
[1] Eric S. Lander,et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.
[2] R. Macdermott,et al. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. , 1999 .
[3] P. Boyer. New insights into one of nature's remarkable catalysts, the ATP synthase. , 2001, Molecular cell.
[4] D. Willoughby,et al. The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] C. la Vecchia,et al. Alcohol and the risk of cancers of the stomach and colon-rectum. , 1994, Digestive diseases.
[6] B. Staels,et al. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.
[7] S. Mayne,et al. Previous lung disease and risk of lung cancer among men and women nonsmokers. , 1999, American journal of epidemiology.
[8] H P Koeffler,et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] A. Nakajima,et al. PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease , 2001 .
[10] H. Mcdevitt,et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. Ahorn,et al. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth , 2002, Oncogene.
[12] G. Hannon,et al. A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.
[13] Johan Auwerx,et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.
[14] M. Moore. Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing , 2002, Journal of cellular biochemistry. Supplement.
[15] D. Kwiatkowski,et al. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families , 2000, Thorax.
[16] S. Steinberg,et al. An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. , 2000, Blood.
[17] K. Ley. Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants , 2001, Immunologic research.
[18] J. Mok,et al. Analysis of TNFB and TNFA NcoI RFLP in colorectal cancer. , 1998, Molecules and cells.
[19] R. Zinkernagel,et al. Arterial inflammation and atherosclerosis. , 2002, Trends in cardiovascular medicine.
[20] V. Perry,et al. The contribution of inflammation to acute and chronic neurodegeneration. , 1998, Research in immunology.
[21] Takuji Tanaka,et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. , 2001, Cancer research.
[22] Y. Arakawa,et al. Helicobacter pylori, neutrophils, interleukins, and gastric epithelial proliferation. , 1997, Journal of clinical gastroenterology.
[23] P. Gøtzsche. Non-steroidal anti-inflammatory drugs , 2000, BMJ : British Medical Journal.
[24] M. Lathrop,et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. , 2002, Cardiovascular research.
[25] A. Watson,et al. Lessons from genetically engineered animal models. VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[26] F. Green,et al. Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.
[27] E. Riboli,et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.
[28] F. Pociot,et al. Cytokine gene polymorphism in human disease: on-line databases , 1999, Genes and Immunity.
[29] M. Stumvoll,et al. Insulin Resistance and Insulin Sensitizers , 2001, Hormone Research in Paediatrics.
[30] S. Feig. IARC Handbooks of Cancer Prevention , 2003 .
[31] Peter Beighton,et al. de la Chapelle, A. , 1997 .
[32] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[33] H P Koeffler,et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.
[34] G. Chrousos,et al. Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity , 2002, Annals of the New York Academy of Sciences.
[35] B. Spiegelman,et al. Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .
[36] J. Powell,et al. Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms , 2001, Circulation.
[37] C. Plass,et al. Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population , 2000, Journal of medical genetics.
[38] J. Chun,et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. , 2001, Cancer letters.
[39] Miller,et al. Experimental evidence from an animal model of adenocarcinoma that chronic inflammation enhances lung cancer risk , 2000, Chest.
[40] K. Okita,et al. Metaplastic polyp of the colon develops in response to inflammation , 1999, Journal of gastroenterology and hepatology.
[41] Y. Matsuzawa,et al. Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. , 2002, Life sciences.
[42] P. Vineis,et al. Metabolic gene polymorphism frequencies in control populations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[43] E. Hawe,et al. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.
[44] A. Nusrat,et al. Interaction of bacteria and bacterial toxins with intestinal epithelial cells , 2001, Current gastroenterology reports.
[45] J Hart,et al. Inflammation. 1: Its role in the healing of acute wounds. , 2002, Journal of wound care.
[46] J. Gilbert,et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. , 2000, American journal of human genetics.
[47] F. Pociot,et al. Cytokine gene polymorphism in human disease: on-line databases, Supplement 2 , 2002, Genes and Immunity.
[48] J. Auwerx,et al. The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.
[49] J. Rhodes,et al. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. , 2002, Trends in molecular medicine.
[50] P. Weber,et al. Phytanic acid, a natural peroxisome proliferator‐activated receptor agonist, regulates glucose metabolism in rat primary hepatocytes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[51] T. Pritts,et al. Mucosal and enterocyte IL-6 production during sepsis and endotoxemia--role of transcription factors and regulation by the stress response. , 2002, American journal of surgery.
[52] L. Schwartz,et al. Inflammatory mediators of experimental colitis in rats. , 1989, Gastroenterology.
[53] B. Epe,et al. Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. , 2002, Carcinogenesis.
[54] A. Rumley,et al. Interleukin-6 Gene −174G>C and −572G>C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[55] D. Malo,et al. The Lps locus: Genetic regulation of host responses to bacterial lipopolysaccharide , 1999, Inflammation Research.
[56] R. Cortese,et al. The two C/EBP isoforms, IL6DBP/NFIL6 and CEBP6δ/NFIL63, are induced by IL6β to promote acute phase gene transcription via different mechanisms , 1993 .
[57] Xianglin Shi,et al. Diseases caused by silica: mechanisms of injury and disease development. , 2002, International immunopharmacology.
[58] R. Coffey,et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.
[59] S. Weitzman,et al. Chronic inflammation and cancer. , 2002, Oncology.
[60] Samuel Singer,et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.
[61] Y. Matsuzawa,et al. Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.
[62] S. Cannistra,et al. Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases , 2001, Human Genetics.
[63] L. Sachs,et al. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[64] S. Nomoto,et al. Polymorphism of tumor necrosis factor in esophageal, gastric or colorectal carcinoma. , 2001, Hepato-gastroenterology.
[65] R. Pounder,et al. Helicobacter pylori: from the benign to the malignant. , 1999, The American journal of gastroenterology.
[66] P. O'connor,et al. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. , 1995, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[67] G. Fantuzzi,et al. Production of IL‐1 receptor antagonist by hepatocytes is regulated as an acute‐phase protein in vivo , 2001, European journal of immunology.
[68] J S Yudkin,et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.
[69] M. Kondo,et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. , 2000, Biochemical and biophysical research communications.
[70] C. FordAlexander,et al. ULCERATIVE colitis. , 1997, Journal of the American Medical Association.
[71] J. McCann. Esophageal cancers: changing character, increasing incidence. , 1999, Journal of the National Cancer Institute.